James Mullen Biography and Net Worth

CEO of Editas Medicine

James (Jim) Mullen joined the Editas Medicine Board of Directors as Chairman in March 2018 and in February 2021 was appointed as President and CEO.

Jim is a recognized biotech leader with more than 40 years of experience building leading biotechnology and pharmaceutical organizations on a global scale. Previously, he served as Chief Executive Officer of Patheon NV, a leading global provider of pharmaceutical development and manufacturing services, until its acquisition by Thermo Fisher Scientific, Inc. (Thermo Fisher), in August 2017. Before joining Patheon, Jim served as Chief Executive Officer and President at Biogen, Inc. (Biogen), one of the world’s largest biotechnology companies. Prior to being named Chief Executive Officer, he held various operating positions at Biogen, including Chief Operating Officer, Vice President, International, and Vice President, Operations.

Jim also serves on the Board of Directors of Thermo Fisher Scientific. He previously served on the Board of Directors of Patheon, Biogen, and PerkinElmer, Inc. He was also Chairman of the Board of Directors of the Biotechnology Innovation Organization.

Jim holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

How do I contact James C. Mullen?: The corporate mailing address for Mr. Mullen and other Editas Medicine executives is 11 Hurley Street, Cambridge MA, 02141. Editas Medicine can also be reached via phone at (617) 401-9000 and via email at [email protected]. Learn More on James C. Mullen's contact information.
Has James C. Mullen been buying or selling shares of Editas Medicine?: James C. Mullen has not been actively trading shares of Editas Medicine during the past quarter. Most recently, James C. Mullen sold 13,805 shares of the business's stock in a transaction on Monday, October 18th. The shares were sold at an average price of $38.03, for a transaction totalling $525,004.15. Learn More on James C. Mullen's trading history.
Who are Editas Medicine's active insiders?: Editas Medicine's insider roster includes Katrine Bosley (CEO), Bruce Eaton (EVP), Lisa Michaels (EVP), James Mullen (CEO), and Michelle Robertson (CFO). Learn More on Editas Medicine's active insiders.
Are insiders buying or selling shares of Editas Medicine?: During the last year, Editas Medicine insiders bought shares 1 times. They purchased a total of 45,000 shares worth more than $253,800.00. During the last year, insiders at the sold shares 9 times. They sold a total of 131,534 shares worth more than $1,101,562.89. The most recent insider tranaction occured on September, 4th when EVP Baisong Mei sold 518 shares worth more than $1,771.56. Insiders at Editas Medicine own 1.9% of the company. Learn More about insider trades at Editas Medicine.
Information on this page was last updated on 9/4/2024.

James C. Mullen Insider Trading History at Editas Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/18/2021	Sell	13,805	$38.03	$525,004.15

James C. Mullen Buying and Selling Activity at Editas Medicine

Editas Medicine Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Today's Range

Now: $2.38

$2.30

$2.45

50 Day Range

MA: $3.26

$2.41

$3.95

2 Week Range

Now: $2.38

$2.30

$11.69

Volume

1,396,319 shs

Average Volume

1,935,229 shs

Market Capitalization

$196.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.01

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW